Denali Therapeutics climbs after US FDA approves co's genetic disorder therapy

Shares of Denali Therapeutics DNLI.O up 3.6% at $21.72 after the U.S. Food and Drug Administration approves co's treatment for a rare genetic disorder

Marketed as Avlayah, the enzyme replacement therapy is aimed at treating Hunter syndrome

Hunter syndrome is caused by lack of the iduronate‑2‑sulfatase enzyme, which leads to buildup of certain sugar molecules in the brain and the body

Avlayah is designed to replace the missing enzyme and address underlying disease progression

Approval marks the first regulatory clearance in the U.S. for DNLI

Including session moves, DNLI stock up 32.4% YTD, following a 18.9% drop in 2025